The class of medications known as GLP-1 receptor agonists is changing the game in weight loss, metabolic health and now even addiction medicine. Drugs like semaglutide (branded as Ozempic and Wegovy) and tirzepatide (branded as Mounjaro and Zepbound) were originally developed for diabetes and obesity—but emerging research now suggests they may also impact behaviors tied to addiction, including drug addiction and alcohol addiction.
If you’re exploring a GLP-1 program, TeleMedsForMe can help you find the right path. Below are five key take-aways about GLP-1s and addiction.
The primary mechanism of GLP-1 medications is metabolic: they simulate a gut hormone that slows digestion, increases fullness and improves insulin secretion. But what’s emerging is that these drugs may also influence the brain’s reward pathways—those same circuits that drive substance use and addictive behaviors.
For instance, when semaglutide crosses the blood-brain barrier, it can modulate dopamine release and reduce the intensity of reward from addictive substances or behaviors. That’s why scientists are investigating GLP-1s for alcohol use disorder, nicotine or opioid use.
What this means: when you’re on a GLP-1 like Ozempic or Wegovy, it’s not just about controlling appetite—it may also change how your brain responds to triggers. TeleMedsForMe’s provider network can evaluate whether a GLP-1 program fits you medically and psychologically.
In studies, GLP-1 treatments have shown promising results in reducing cravings for alcohol and other addictive substances. A recent summary pointed out that semaglutide reduced laboratory alcohol self-administration and lowered drinks per drinking day in people with alcohol use disorder.
There’s even data indicating that GLP-1 users have lower rates of overdose in opioid use disorder contexts.
While these results are preliminary, they highlight a potential “bonus” benefit of GLP-1s: fewer compulsive urges, whether to food, alcohol, or other substances. If you’re on a GLP-1 program through TeleMedsForMe, your provider will monitor not only weight and metabolic outcomes—but also any changes in addictive behaviors or cravings.
It’s crucial to understand that GLP-1s like semaglutide or tirzepatide are not approved primary therapies for addiction (yet). While promising, the research is still evolving, particularly for drug and alcohol addictions.
Therefore:
TeleMedsForMe connects you with clinicians who evaluate those nuances.
When starting a GLP-1 program with addiction history or risk, here are critical discussion points:
a) Medical screening – Are you cleared for use of semaglutide, Mounjaro, Wegovy, Zepbound? Do you have comorbid conditions (diabetes, liver disease, substance use disorder) that require extra care?
b) Addiction history – Talk about past drug or alcohol addiction, cravings, emotional triggers. Your provider should tailor monitoring accordingly.
c) Behavioral changes – Since GLP-1s might reduce cravings, note whether you feel less desire for substances, but also check if you feel emotionally “flat” or less motivated.
d) Integration with addiction care – If you’re in therapy or a recovery program, ensure coordination between your addiction specialist and your GLP-1 prescriber.
e) Follow-up and monitoring – TeleMedsForMe programs include ongoing virtual visits to track not just weight and metabolic health—but also mood, sleep, cravings, and overall functioning.
By checking all these boxes, you help ensure safe and effective use of GLP-1s in the context of addiction risk or recovery.
Research is accelerating. Pharmaceutical companies and academic labs are actively exploring GLP-1 agonists for alcohol use disorder (AUD), opioid use disorder (OUD), and even nicotine dependence.
Some future possibilities:
For you as a patient: it means that if you’re eligible, starting GLP-1 therapy may carry benefits beyond weight loss—potentially reducing addictive cravings or relapse risk. Still, the decision should be made with your medical provider and addiction specialist, not as a standalone approach.
At TeleMedsForMe, we understand that prescribing a GLP-1 like semaglutide or tirzepatide isn’t just about weight—it’s about whole-body wellness, emotional health, and behavioral change. Here’s how we help:
If you’re considering a GLP-1 like Ozempic, Wegovy, Mounjaro or Zepbound and want a provider attuned to both metabolic and addiction-related issues, TeleMedsForMe can connect you safely and smoothly.
With the massive uptake of GLP-1 drugs such as semaglutide and tirzepatide for obesity and diabetes, their unexpected effects on the brain’s reward and craving circuitry are drawing significant attention. For people with drug addiction or alcohol addiction (or at risk of either), these medications may offer a new tool—though not a standalone solution.
Here are the key take-aways:
This intersection of weight-loss pharmacology and addiction medicine is still evolving—but it holds real promise. If you’re on (or considering) a GLP-1 program and have an addiction history or behavioral-health concern, reach out to TeleMedsForMe for expert guidance and a full evaluation.
GLP1 medications can produce meaningful weight loss, especially in the first several months of treatment. Many people see steady progress as appetite decreases and eating patterns become easier to manage. But eventually, the scale slows down. Or stops entirely. This is called a plateau, and it is one of the most common and frustrating parts […]
GLP1 medications have helped millions of people lose weight and improve blood sugar control. But as results become visible, a common question comes up: Is this medication actually fixing my metabolism, or is it just making me eat less? The answer is more nuanced than many people realize. GLP1 medications absolutely reduce appetite, but their […]
Losing weight on a GLP1 medication is one phase of the journey. Maintaining that weight loss is another. While these medications are powerful tools for appetite regulation and metabolic improvement, long term success depends on more than the prescription itself. Whether you plan to stay on your GLP1 long term or are considering tapering, understanding […]